848398-41-4

Basic information

• Product Name: 2,4-DICHLORO-5,7-DIHYDROFURO[3,4-D]PYRIMIDINE
• Synonyms: 2,4-DICHLORO-5,7-DIHYDROFURO[3,4-D]PYRIMIDINE
• CAS NO: 848398-41-4
• Molecular Formula: C₆H₄Cl₂N₂O
• Molecular Weight: 191.01476
• Product Categories: pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 848398-41-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 337.837 °C at 760 mmHg
• Flash Point: 158.118 °C
• Appearance: /
• Density: 1.593 g/cm³
• Vapor Pressure: 0.0002mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.43±0.20(Predicted)
• CAS DataBase Reference: 2,4-DICHLORO-5,7-DIHYDROFURO[3,4-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-5,7-DIHYDROFURO[3,4-D]PYRIMIDINE(848398-41-4)
• EPA Substance Registry System: 2,4-DICHLORO-5,7-DIHYDROFURO[3,4-D]PYRIMIDINE(848398-41-4)

Safety Data

• Hazardous Substances Data: 848398-41-4(Hazardous Substances Data)

Usage

Uses

2,4-Dichloro-5,7-dihydrofuro[3,4-d]pyrimidine is used as a reagent in the synthesis of substituted pyrimidinediamines as potent dual BRD4-kinase inhibitors for treating cancer.

InChI:InChI=1/C6H4Cl2N2O/c7-5-3-1-11-2-4(3)9-6(8)10-5/h1-2H2

Upstream product

• 89898-51-1 ethyl tetrahydrofuran-3-one 4-carboxylate 
• 848398-40-3 5,7-dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione 

Downstream Products

• 1542710-75-7 N-benzyl-2-(2-methyl-2H-indol-1(7aH)-yl)-5,7-dihydrofuro[3,4-d]pyrimidin-4-amine 

Relevant articles and documents

FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX

Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS

CRF antagonists comprising as an active ingredient, the compound of formula (I) wherein A ring is 5-6 membered mono-cyclic ring which may be substituted; B ring is 5-7 membered unsaturated mono-heterocyclic ring which may be contained another 1-2 of hetero atom(s) and substituted by another substituents; W1 and W2 is carbon atom or nitrogen atom; Z is NR3, oxygen atom, sulfur which may be oxidized or CR4R5; R' is alkyl, alkenyl or alkynyl that may be substituted, amino which may be protected, hydroxyl which may be protected, S(O)nR6, COR7, or cyclic group which may be substituted; R2 is unsaturated cyclic group which may be substituted.